KidneyIntelX™ has been

validated in two large cohorts;

Results you can count on.

Maintain

~50%

of patients are expected to have a low-risk score

Patients are likely to have stable kidney function over the next five years

Follow up at least annually

Monitor

~35%

of patients are expected to have an intermediate-risk score

Patients are at an average risk for progression to ESKD

May need modification and a specialist consultation

Follow-up at least 2x year

Act

~15%

of patients are expected to have a high-risk score

Patients at elevated risk for progression to ESKD

Will require aggressive lifestyle changes, medication management and specialist referrals

Plus, real-world evidence demonstrates that

PCPs want this tool.

98%

Percentage of PCPs who would adopt KidneyIntelX to identify adult patients with type 2 diabetes and CKD who are at risk of accelerated kidney function decline

2X

More likely to appropriately prescribe SGLT2 inhibitors (SGLT2i) and angiotensin II receptor blockers (ARB) for their high-risk patients

Nearly 3X

More likely to appropriately refer their high-risk patients to a specialist

Real World Results
About Test
See Evidence
Growing # of Plans